,M) or to a mixture of both. After centrifugation, pellets were drained free of supernatant, lOdul N HCI 04 was added and 2 ,ul aliquots subjected to high voltage electrophoresis on paper to separate the metabolites. The regions corresponding to Ara-C, AraU the Ara-C phosphates and the equivalent metabolites of 6-TG were cut out and estimated by liquid-scintillation counting. The metabolic products of one drug were not affected by the presence of the other with the exception that in 12/57 cases the production of Accepted 11 August 1978 AraU from Ara-C was reduced by 6-TG. This reduction varied from 20-100%, suggesting an effect of 6-TG upon Ara-C deamination. It is known that 6-TG inhibits some enzymes of nucleic-acid biosynthesis, but inhibition of cytidine deaminase has not been reported (Sartorelli & Lepage, 1958) . Therefore, the kinetics of such deamination were investigated. Cells from a suitable blast population were diluted with 3 volumes of water, disintegrated by 5 cycles of freeze thawing and centrifuged at 20,000 g for 1 h. The supernatant was used as a crude deami- nase preparation to the extent of 50,p1/ml substrate (Ara-C) at pH 7-5. Ara-C concentrations were varied from 50 to 400 uM and the deamination was stopped after various times by addition of N HC104. The extent of deamination was estimated from the extinction at 290 nm (em (290) Ara-C = 9,6 x 103, AraU = 0*3 x 103). In a separate experiment, 200 pM 6-TG was also added during incubation.
In the Figure (Camiener, 1967) .
The inhibitory effect of 6-TG upon cytidine deaminase which has been described suggests that the synergistic effect of the combination of Ara-C and 6-TG may, in some cases at least, be the result of an increase in the half-life of Ara-C brought about by 6-TG. Such an effect has been reported in mice (Pittillo & Woolley, 1973) . Data of LePage & Whitecar (1971) suggest that levels of 15Mm of 6-TG may be maintained for some hours following a single oral administration of the drug in human subjects. Measurements could be made of the half-life of Ara-C during its first administration, and compared with the half-life in subsequent adminstrations, after several dosages of 6-TG in a combination schedule. This would show whether the reported inhibition of deaminase has any clinical relevance for the scheduling of the two drugs.
